The BC-based producer continues global expansion flurry since unveiling merger deal with Aphira

Tilray Inc. (NASDAQ:TLRY)

VANCOUVER, BC, CANADA, February 10, 2021 /EINPresswire.com/ -- Shares of Tilray Inc. (Nasdaq: TLRY) continue to rally as the Canadian producer signed a medical cannabis supply deal in the United Kingdom.

Tilray stock climbed over 40 per cent to US$42.35 when the Nasdaq closed on Tuesday.

The British Columbia-based operator says it will import product to U.K. medical cannabis distributor Grow Pharma to authorized patients in England, Scotland, Wales and Northern Ireland.

It’s the fourth international supply deal Tilray’s reported since the firm said it was combining operations with its rival Aphria Inc. (TSX: APHA) on Dec. 16.

Since the $5 billion merger agreement was unveiled, shares in Tilray have surged 438 per cent. The new company will keep Tilray’s name and trade under TLRY on the Nasdaq.

The companies say the deal will create a new leader in the global pot sector after it closes in the second quarter of 2021.

On Feb. 4, Tilray said its medical cannabis products were available in 17 countries around the world after inking a supply deal with Worldpharma Biotech to import product into Spain.

Tilray said last week it’s the first company allowed to sell medical cannabis products in Portugal.

The firm says the Portuguese government awarded it the first national supply contract to sell pharmaceutical-grade weed from its GMP-certified facility based in the country.

Gaining market approval from the Portuguese national authority Infarmed was a big win, Tilray said, because it means more supply deals inside the European Union.

In January, the firm was selected by the French government to supply medical cannabis from its Portuguese facility as part of an 18–24 month experiment in France.

Aphria is also eyeing the growing European medical market. The firm owns a major pharmaceutical distribution business inside Germany, CC Pharma, which signed a contract last month to start selling Aphria’s medical cannabis brand there.

Aphria said Monday it promoted its chief strategy officer and consumer packaged goods veteran, Denise Faltischek, to lead its German operations. The company remains on track to be the first licensed medical cannabis producer in Germany, according to a statement.

Original post found here: https://mugglehead.com/tilray-stock-soars-40-on-uk-supply-deal-with-grow-pharma/

About Mugglehead

Mugglehead.com is a digital publisher dedicated to cannabis news, investments, culture, and science, owned by Mugglehead Media Corp. We publish original content, including video, interviews and articles. Because many of the companies and trends we cover are related to investments and stocks within the cannabis industry, please review our disclaimer and forward-looking statements below.

Original content created by Mugglehead Media Corp. © 2021 is protected by copyright laws.

Visit us at https://mugglehead.com daily for all things cannabis-related.

Facebook: https://www.facebook.com/muggleheadmedia

Twitter: https://twitter.com/muggleheadmedia

Disclaimer and Forward-Looking Statements

Mugglehead Media Corp. and Mugglehead.com (collectively, Mugglehead) is a news and media publisher dedicated to cannabis, psychedelics, and mental wellness. It is not registered as an investment adviser, broker-dealer or other financial or securities professional with any financial or securities regulatory authority. You understand that no content published by Mugglehead constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Mugglehead does not render general or specific investment advice and does not endorse or recommend the business, products, services or securities of any industry or company mentioned on this Site.
This news release is not an offer to sell or a solicitation of an offer to buy any securities or commodities. To the extent that anything in this press release may be deemed to be investment advice or a recommendation in connection with a particular company or security, such information is impersonal and is not tailored to the needs of any specific person.
From time to time, Mugglehead (on behalf of itself and any partner, director, officer or insider of Mugglehead) may have a financial or other interest in the party or parties featured on the Site, within the meaning of National Instrument 31-103 - Registration Requirements, Exemptions, and Ongoing Registrant Obligations, published by the Canadian Securities Administrators, as a result of ownership of securities in, compensation received or receivable from or other financial arrangement with such party or parties featured in this press release. We will disclose if we have a position in any such party or parties, as at the date of publication of this press release; however, we may not update this disclosure after such date.
In addition to historical information, this press release may contain forward-looking statements, including statements with respect to third parties regarding product plans, future growth, market opportunities, strategic initiatives, industry positioning, customer acquisition, the amount of recurring revenue and revenue growth. In addition, when used in this release, the words ''will,'' ''expects,'' ''could,'' ''would,'' ''may,'' ''anticipates,'' ''intends,'' ''plans,'' ''believes,'' ''seeks,'' ''targets,'' ''estimates,'' ''looks for,'' ''looks to,'' ''continues'' and similar expressions, as well as statements regarding a third party's focus for the future, are generally intended to identify forward-looking statements. Each of the forward-looking statements we make in this press release involves risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those disclosed by the companies featured in this release in their public securities filings. You should carefully review the risks described therein. You should not place undue reliance on these forward-looking statements, which speak only as of the date such statement was published. Mugglehead undertakes no obligation to publicly release any updates or revisions to the forward-looking statements or reflect events or circumstances after the date of their publication, except as required by law.
From time to time, reference may be made in this press release to prior articles or opinions we have published. These references may be selective, may reference only a portion of an article or opinion, and are likely not to be current. As market information changes continuously, previously published information and data, and any references thereto, may not be current and should not be relied upon.

Nick Laba
Mugglehead Media Corp
+1 (888) 684-4534
email us here
Visit us on social media:
Facebook
Twitter

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.